FCRL5

FCRL5 Molekülinformation

Englischer NameFc receptor-like protein 5Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-AliasFc Receptor-Like 5,CD307e Antigen,PRO820,CD307e,Fc Receptor Like 5,FcR-like protein 5,BXMAS1,Fc receptor homolog 5,FcRH5,Immune receptor translocation-associated protein 2,CD_antigen: CD307e,IRTA2,Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2)
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameFc receptor-like protein 5
Target-AliasFc Receptor-Like 5,CD307e Antigen,PRO820,CD307e,Fc Receptor Like 5,FcR-like protein 5,BXMAS1,Fc receptor homolog 5,FcRH5,Immune receptor translocation-associated protein 2,CD_antigen: CD307e,IRTA2,Immunoglobulin Superfamily Receptor Translocation Associated 2 (IRTA2)
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

FCRL5 Molekülhintergrund

May be involved in B-cell development and differentiation in peripheral lymphoid organs and may be useful markers of B-cell stages. May have an immunoregulatory role in marginal zone B-cells.

FCRL5 Molekülalias

BXMAS1, CD307, CD307e, FCRH5, IRTA2, PRO820

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
Anti-FcRL5 CAR-T Cell Therapy(Xuzhou Medical University)Phase 2 ClinicalXuzhou Medical University (Xzmu)Multiple Myeloma
Details
CevostamabRG-6160; BFCR-4350A; RO-7187797Phase 2 ClinicalGenentech IncLupus Erythematosus, Systemic; Multiple Myeloma
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation